Chih-Chun Chang

Chih-Chun Chang

Auto-generated profile, based on publicly available information

Chih-Chun Chang

Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, 30013 Hsinchu, Taiwan, Republic of China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JSJen-Shin Song
Jen-Shin Song
CCChih-Chun Chang
Chih-Chun Chang
CWChien-Huang Wu
Chien-Huang Wu
TDTrinh Kieu Dinh
Trinh Kieu Dinh
JJJiing-Jyh Jan
Jiing-Jyh Jan
YCYunching Chen
Yunching Chen
Significance: A highly selective, safe, and potent CXCR4 antagonist, BPRCX807, has been designed and experimentally validated in various hepatocellular carcinoma models. Through combination therapy, it can synergize with either a kinase (e.g., sorafenib) or checkpoint inhibitor (e.g. anti–PD-1) to augment effectiveness of current anticancer treatments. With its unique mode of action, a new anticancer strategy for preventing cell migration and metastasis is provided.

17 December 2025 in bioRxiv
Verified
Preprint
Open access
CCChih-Chun Chang
Chih-Chun Chang
LSLei Shi
Lei Shi
SCSoon H. Choi
Soon H. Choi
APAndrea Pennati
Andrea Pennati
VVVasiliki Valkanioti
Vasiliki Valkanioti
JGJacques Galipeau
Jacques Galipeau
Engineering T and natural killer (NK) cells with chimeric antigen receptors (CAR) creates effective adoptive cell transfer therapies for cancer treatment. However, using viral transduction as a primary genetic modification method adds regulatory burdens and is expensive to produce at scale. Delivering mRNA encoding CAR via lipid nanoparticles (LNPs) has been explored as a potent non-viral method to generate CAR immune cells. Still, it has not been optimized for CAR treatment of neuroblastoma to date. An LNP formulation to deliver mRNA encoding a GD2 CAR into human T and NK cells was designed and characterized by dynamic light scattering for size distribution, z-average diameter, polydispersity index, and ζ potential. Fluorescent reporter detection persisted for more than 1 week after mRNA LNP transfection, without affecting T or NK cell viability. The potency of GD2 CAR T cells with 79.9% reporter positivity and GD2 CAR NK cells with 26.6% reporter positivity was assessed in vitro against the GD2 + neuroblastoma cell line CHLA20. GD2 CAR T or CAR NK cells could effectively target and kill neuroblastoma cells in a dose-dependent fashion, and GD2 CAR T cells showed increased IFNγ production. This study shows mRNA LNPs are a promising non-viral approach for generating GD2 CAR T and CAR NK cells, potentially offering a safer and more cost-effective alternative to current viral vector-based methods.